Laxmi Dental Reports Record Q1 FY27 Revenue of ₹75 Cr, PAT Up 23.8%

Laxmi Dental Limited reported a strong start to FY27, with Q1 revenue reaching its highest-ever quarterly level of ₹74.7 crore, up 13.9% year-on-year. The company also delivered healthy profitability, with EBITDA rising 20.6% YoY to ₹14.4 crore and PAT increasing 23.8% to ₹10.3 crore. During the earnings call, management discussed the performance of its dental laboratory and aligner businesses, international expansion, scanner adoption, digitalisation, AI-led automation, capacity, the proposed Palghar facility and its growth strategy for the coming quarters.

Q1 FY27 Results

Laxmi Dental reported Q1 FY27 revenue from operations of ₹74.7 crore, compared with ₹65.6 crore in Q1 FY26. Gross profit increased 22.1% YoY to ₹58.7 crore, while the gross margin improved to 78.6%. EBITDA increased 20.6% YoY to ₹14.4 crore, with the EBITDA margin improving to 19.2% from around 18% in the year-ago period. PAT stood at ₹10.3 crore, registering 23.8% YoY growth, with a PAT margin of 13.8%. The company remained debt-free, with finance costs at only ₹0.3 crore.

Segment Performance

The dental laboratory business remained a key growth driver, recording 23.5% YoY revenue growth, while the international business grew an impressive 37.4% YoY. The aligner solutions business also delivered strong growth of 28.6% YoY, with Bizdent growing 27.8% and Vedia increasing 29.3%. Meanwhile, Kids-e-Dental continued its strong growth trajectory, registering 54.4% YoY growth during the quarter.

Capex and New Facility Plans

Management said it plans to invest in new machinery during FY27 to modernise and expand manufacturing capacity and improve operational efficiency. The company has also executed a Letter of Intent for acquiring land in Palghar, Maharashtra. The proposed facility is expected to replace the company’s two rented domestic facilities with a unified owned facility. Management currently spends close to ₹2 crore annually on rent for these properties and believes the new facility can provide substantially greater capacity and room for future expansion. The company indicated that the new facility could potentially be around three times the size of the current facilities.

The transition is expected to be carried out in a phased manner, with management stating that it does not anticipate a significant disruption to revenue or productivity.

Future Growth Plans

Laxmi Dental plans to focus on market expansion, product innovation, digitalisation and brand building. Management expects domestic dental laboratory growth to accelerate over the coming quarters as previously deployed scanners mature and begin generating additional business. The company estimates that scanner-related business typically has a six-month to one-year gestation period, with some cases taking up to 18 months.

The company also expects to deploy around 800–1,000 scanners during FY27, subject to demand and technology developments. Scanner adoption in the industry is currently estimated at only around 7–8%, according to management, suggesting significant room for further digitisation.

Management’s stated aspiration remains 15–20% revenue growth and an 18–20% EBITDA margin.

Management Commentary

Management highlighted that the company’s competitive advantage is built around trust, quality, experience and technology. Laxmi Dental has been operating in the dental industry for around 36 years and believes this established relationship with dentists provides an important advantage. The company also emphasised its global quality standards, innovation and product development.

The management remains positive about international expansion and has appointed a new CEO for its US business with more than three decades of experience in the medical devices and dental industry. The company expects this appointment to strengthen its US operations and help accelerate growth in the region.

On margins, management said the scanner business typically generates a trading margin of around 15–20%, which can create some quarter-to-quarter fluctuation in gross margins. However, excluding scanners, management expects the underlying margins to remain stable or improve as the business mix becomes more favourable.

Important Discussion Points from the Earnings Call

One important discussion was around AI-led automation. The company is already working with AI-based crown models in the beta stage. Management said the initial costs are currently elevated, but expects the cost structure to improve as these technologies scale.

Another key point was the company’s digital penetration. Domestic digital penetration across the dental laboratory and aligner businesses is currently estimated at around 75–80%, while international operations are predominantly digital.

The company also clarified that its aligner strategy remains B2B through dentists rather than direct-to-consumer. It does not plan to sell aligners directly to patients. Management believes increasing education and training among general dentists can expand the addressable market for aligners.

On competition, management acknowledged that competition in the aligner market will remain, but said the company intends to compete through innovation, dentist education, branding, and cross-selling its products to its existing customer base.

Instead, the transcript provides operational indicators such as scanner deployment, capacity utilisation, international expansion and expected growth, which are more relevant to assessing the company’s future business momentum.

Disclaimer

This article is based on the Q1 FY27 earnings conference call transcript and information provided by Laxmi Dental Limited. The views, expectations, targets, and forward-looking statements mentioned by management are subject to business, market, and other risks and uncertainties. This article is for informational and educational purposes only and should not be considered investment advice, a recommendation to buy or sell securities, or a guarantee of future performance. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.